
    
      To evaluate the proportion of β-thalassemia patients who have an erythroid response, defined
      as:

        1. a hemoglobin increase of ≥ 1.5 g/dL from baseline for ≥ 14 days (in the absence of red
           blood cell [RBC] transfusions) in non-transfusion dependent patients, or

        2. ≥ 20% reduction in RBC transfusion burden compared to pretreatment in transfusion
           dependent patients.
    
  